Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

568
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
568
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.1K
The pathophysiology of pneumonia involves the following steps:
2.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

662
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
662
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.1K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.1K
Pneumonia IV: Management01:28

Pneumonia IV: Management

624
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
624
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

826
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
826

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between negative-pressure ICU rooms and the risk of COVID-19-associated pulmonary aspergillosis: an ancillary analysis of the COVID-ICU cohort study.

Critical care (London, England)·2026
Same author

Visual Right Ventricular Assessment in ICU: A Multicenter International Study.

Critical care medicine·2026
Same author

Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.

Cell·2026
Same author

Cardiogenic shock in heart transplant recipients: A multicenter cohort study with matched analysis.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

A consensus of international experts on definition, sampling, treatment, and prevention of peripheral extracorporeal membrane oxygenation cannula-site infection obtained by the Delphi method: the SAVECMO study.

Intensive care medicine·2026
Same author

Epidemiology of pain, delirium, psychiatric disorders, discomfort and sedation-analgesia management in the intensive care unit: a one-day nationwide study.

Critical care (London, England)·2025
Same journal

[From rhizomania to viral RNAs structure functions].

Virologie (Montrouge, France)·2026
Same journal

[Characteristics of viral gastroenteritis in solid organ transplant patients].

Virologie (Montrouge, France)·2026
Same journal

[ResaFlu/FluResearchNet International symposium,Toulouse, November 26-27, 2025].

Virologie (Montrouge, France)·2026
Same journal

[ViRAE 2025: a landmark inaugural edition for virology at INRAE].

Virologie (Montrouge, France)·2026
Same journal

[13<sup>rd</sup> Cytokines annual meeting, Novembre 2-5 2025, Seattle, USA].

Virologie (Montrouge, France)·2026
Same journal

[Annual report of the French Society for Virology].

Virologie (Montrouge, France)·2026
See all related articles

Related Experiment Video

Updated: Dec 3, 2025

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.3K

[Herpes simplex virus pneumonia].

Charles-Edouard Luyt1

  • 1Service de Médecine intensive réanimation, Institut de Cardiologie, Groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Sorbonne Université.

Virologie (Montrouge, France)
|October 28, 2020
PubMed
Summary
This summary is machine-generated.

Herpes simplex virus 1 (HSV-1) frequently reactivates in ICU patients, potentially causing lung infections. Acyclovir may benefit those with confirmed HSV-1 bronchopneumonitis or high viral loads.

Keywords:
cytomegalovirusherpes simplex virus 1intensive care unitpneumoniavirus reactivation

More Related Videos

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation
12:22

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation

Published on: April 2, 2012

17.8K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K

Related Experiment Videos

Last Updated: Dec 3, 2025

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
07:27

Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK

Published on: December 18, 2012

12.3K
A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation
12:22

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation

Published on: April 2, 2012

17.8K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K

Area of Science:

  • Virology
  • Critical Care Medicine
  • Infectious Diseases

Background:

  • Herpes simplex virus 1 (HSV-1) reactivation is common in intensive care unit (ICU) patients, occurring in 20% to 50% of cases.
  • Reactivation typically starts in the throat and progresses to the respiratory tract and lungs within 7 to 10 days of hospital admission.
  • HSV-1 bronchopneumonitis is a rare but serious complication, defined by clinical symptoms, lower respiratory tract HSV-1 presence, and specific laboratory findings.

Purpose of the Study:

  • To investigate the role of HSV-1 reactivation in ICU patient mortality.
  • To evaluate the efficacy of acyclovir for prophylactic, preemptive, and curative treatment of HSV-1 infections in the ICU setting.
  • To establish recommendations for managing HSV-1 reactivation in critically ill patients.

Main Methods:

  • Review of existing randomized trials and observational studies on HSV-1 reactivation and acyclovir treatment in ICU patients.
  • Analysis of diagnostic criteria for HSV-1 bronchopneumonitis, including clinical symptoms and viral load quantification in bronchoalveolar lavage (BAL) fluid.
  • Assessment of the association between HSV-1 reactivation and patient mortality.

Main Results:

  • HSV-1 reactivation is linked to increased mortality in ICU patients, though its direct contribution is unclear.
  • Randomized trials found no benefit from prophylactic or preemptive acyclovir treatment.
  • Observational studies suggest potential benefits of acyclovir when used as a curative treatment for established HSV-1 infections.

Conclusions:

  • Current evidence does not support routine prophylactic or preemptive acyclic use for HSV-1 in ICU patients.
  • Acyclovir is recommended for treating patients diagnosed with HSV-1 bronchopneumonitis or those with high HSV-1 loads (above 10^5 copies/million cells) in BAL fluid.